Search Results for “NHS” – Page 16 – media

Blood tests may spare cancer patients chemo

A blood test which can detect traces of cancer cells could spare thousands of patients unnecessary chemotherapy every year. A major bowel cancer trial is examining whether the test can show if surgery has removed all of the tumour. Doctors say half of patients with stage 3 bowel cancer are cured by surgery alone so by using chemotherapy they are over-treating many people. About 1,600 bowel cancer patients are being recruited to the UK study. Ben Cooke runs a hair salon on the King’s Road in Chelsea, London, and also works as a stylist for fashion shoots. In early March last year, he noticed some dark blood in his poo. He rang NHS 111 and was sent to A&E. He was diagnosed with stage 3 bowel cancer, which was successfully treated with surgery. The gold standard treatment is to then have intravenous chemotherapy to mop ...
- Source: drugdu
- 123
- April 6, 2023
England’s NICE signs off on PTC Therapeutics’ $3.7M gene therapy for ultra-rare disease

The National Institute for Health and Care Excellence (NICE) has recommended the therapy to treat patients with aromatic L-amino acid decarboxylase (AADC) deficiency who are 18 months and older. PTC has inked a confidential discount access scheme to make Upstaza available to the National Health Service (NHS), NICE says. The drug carries a list price of 3 million pounds sterling (around $3.71 million) per 0.5-mL infusion solution before the confidential discount. AADC deficiency is so rare that it affects an estimated 10 children in the U.K., only a few of whom could be eligible for the treatment. The disease causes a wide range of severe symptoms, but around 80% of patients have a severe form that leaves them fully dependent on caregivers and unable to meet normal developmental milestones. Due to the rarity of this condition, there isn’t much research on the expected life span of a person with AADC deficiency. It’s estimated that most ...
- Source: drugdu
- 144
- March 24, 2023
NICE questions value and efficacy of five Covid-19 drugs with rejection

This week, NICE rejected five major Covid-19 therapies due to high costs and uncertainties in clinical evidence. The UK’s National Institute for Health and Care Excellence (NICE) has published a draft guidance that does not recommend the use of five major Covid-19 therapies. This news came as many organisations and patient advocacy groups have been campaigning for the adoption of some of the rejected drugs for several months, amidst concerns about access to medicines in the UK. The therapies with a negative appraisal included three anti-Covid-19 antibodies; Regeneron Pharmaceuticals’ Ronapreve (casirivimab +imdevimab), GSK’s Xevudy (sotrovimab) and, AstraZeneca’s Evusheld (tixagevimab + cilgavimab). Between November 5 and November 12, a total of 20,588 people have reported testing positive for Covid-19 in England, according to government data. This number is likely an underestimation given the lack of testing amongst the population. Furthermore, in that same period, 3,407 patients were admitted to a hospital in the country for severe cases of Covid-19. ...
- Source: drugdu
- 150
- March 17, 2023
NICE approves funding for Novartis gene therapy

Funding is for onasemnogene abeparvovec and concerns babies with spinal muscular atrophy NICE has published final draft guidance regarding the recommendation of routine NHS funding for onasemnogene abeparvovec. The treatment is a potentially curative one-off gene therapy for treating a rare genetic condition, spinal muscular atrophy (SMA). It will be used specifically among babies aged up to 12 months, before they develop symptoms. The drug – also known as Zolgensma – is produced by Novartis Gene Therapies. The recommendation has emerged after NICE reviewed the evidence to determine whether it should be available for routine NHS funding in England and Wales. Onasemnogene abeparvovec is designed to address the genetic cause of SMA and its effects are thought to be life-long. Under NICE’s original guidance, released in 2021, it was recommended for babies before they develop symptoms of SMA as part of a managed access agreement (MAA). The agreement ensured that ...
- Source: drugdu
- 130
- March 17, 2023
Newly introduced Health and Care Bill aims to ‘dispose of unnecessary bureaucracy’

Health and Social Care Secretary Sajid Javid has introduced a new Health and Care Bill to parliament this week, containing proposals to ‘help the NHS build back better from the pandemic’. Earlier this year, the government revealed its proposed plans for the new Bill, with the formal introduction to parliament coming on the heels of ‘extensive’ discussion with NHS England, the Local Government Association and the health and care sector. Among the key measures outlined in the Bill includes plans to bring together the NHS and local government to plan health and care services. Other proposals include the development of a new procurement regime for the NHS and public health procurement, which aims to reduce bureaucracy on commissioners and providers alike. This proposal will also aim to reduce the need for competitive tendering, when it adds limited or no value. The Bill will also ensure that each part of England ...
- Source: drugdu
- 202
- July 7, 2021
Health and Care Bill
Over 600,000 COVID-19 tests genomically sequenced in the UK

The UK has sequenced over 600,000 positive COVID-19 tests, providing ‘invaluable data’ in the fight against the virus, the Department of Health and Social Care (DHSC) announced last Friday. According the DHSC, the UK is estimated to contribute around 23% of all COVID-19 sequencing across the globe uploaded to GISAID. In the early stages of the pandemic, the COVID-19 Genomics UK (COG-UK) consortium was created to enable the delivery of large-scale and rapid whole-genome virus sequencing for local NHS centres and the government. The data collected by COG-UK has aided public health agencies in decision making for managing COVID-19 outbreaks and for informing vaccine development efforts. When sequenced, virus genome data can then be combined with clinical and epidemiological datasets to help inform UK public health interventions and policies. In a statement, the DHSC added that this information will also enable the evaluation of novel treatments and non-pharmacological interventions in ...
- Source: drugdu
- 190
- July 5, 2021
COVID-19 tests
GSK’s PD-1 inhibitor Jemperli approved in the UK

GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer. Specifically, Jemperli (dostarlimab) has been granted a conditional marketing authorisation for use in adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer, who have progressed on or following prior treatment with a platinum containing regimen. The authorisation is based on results from the open-label GARNET study, which included women with recurrent or advanced dMMR/MSI-H endometrial cancer who progressed on or after a platinum-based chemotherapy regimen. Jemperli treatment led to an objective response rate of 44.8% and a disease control rate of 57.1%, while a median duration of response (DoR) had not been reached in these patients. However, the probability of maintaining a response at six months and 12 months was 97.9% and 90.9% respectively, according to ...
- Source: drugdu
- 287
- June 7, 2021
Jemperli
NICE turns down GSK’s IV Benlysta for systemic lupus

The National Institute for Health and Care Excellence (NICE) has rejected NHS funding for an intravenous formulation of GlaxoSmithKline’s Benlysta (belimumab) as an add-on therapy for certain patients with active autoantibody-positive systemic lupus. The preliminary decision, outlined in an appraisal consultation document, relates to use of the drug in people aged five years and older when there is a high degree of disease activity (for example, positive anti-double-stranded DNA, low complement) and despite standard therapy, as per its marketing authorisation. According to NICE, while clinical trial evidence suggests that after a year of treatment Benlysta plus standard therapy reduces disease activity more than standard therapy alone, “the results are uncertain because the trials were short”. Also, it noted that the long-term benefit of Benlysta compared with standard therapy or rituximab is unknown, as long-term extension studies did not have comparator arms. Cost-effectiveness estimates are also uncertain, and are most likely ...
- Source: drugdu
- 326
- June 4, 2021
GSK
NICE green lights Tremfya to treat active psoriatic arthritis

Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s National Institute for Health and Care Excellence (NICE) for the treatment of active psoriatic arthritis (PsA). Tremfya (guselkumab) is a fully human monoclonal antibody (mAb) designed to selectively bind to and inhibit the IL-23 receptor – an key driver of progression in inflammatory diseases such as PsA. NICE’s final appraisal document (FAD) recommends Tremfya to treat moderate-to-severe PsA in adults who have responded inadequately to disease-modifying antirheumatic drug (DMARD) therapy or who cannot tolerate them. The positive recommendation is supported by results from the Phase III DISCOVER-1 and DISCOVER-2 clinical trials, which evaluated the safety and efficacy of Tremfya in adults with active PsA. Across both studies, Janssen’s drug demonstrated a favourable risk-benefit profile, showing statistically significant benefits compared to placebo on disease activity, joint and skin symptoms, functional capacity and health-related quality of life. “[Tremfya] is ...
- Source: drugdu
- 265
- May 31, 2021
Janssen
New report suggests the gender pay gap for doctors increased during pandemic

A new report suggests that the gender pay gap for doctors has increased during the pandemic, with female doctors found to be disproportionately affected by falling earnings. The Medscape UK Doctors’ Salary and Sanctification Survey 2021, conducted between 10 November 2020 to 16 February 2021, includes responses from over 1,000 doctors in England, Scotland, Wales and Norther Ireland. This includes doctors from a range of specialities, with 73% working in the NHS, 23% working in both the NHS and private sector and 4% in the private sector only. The report considers changes in doctors’ average salaries since Medscape’s last salary and satisfaction survey released in 2019. It found that overall, 29% of UK doctors reported a drop in income, compared with 17% in 2019. Some doctors attributed the decrease in earnings to COVID-19 ‘multiple times’, while others cited different reasons. The report also suggests that women have suffered a greater ...
- Source: drugdu
- 262
- April 23, 2021
pandemic

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.